Cervical Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Cervical Cancer is a $819K market dominated by a single asset (TIVDAK) in peak lifecycle stage.
Key Trends
- Extreme market concentration: one product (TIVDAK) represents 86% of spending
- Limited commercial footprint: only 2 products with quantified spending; 5 of 7 products lack revenue data
- Active pipeline with 378 trials across multiple phases, suggesting future competitive pressure
Career Verdict
This is a niche, high-risk specialization with limited near-term growth but potential upside if pipeline candidates succeed.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | TIVDAK (TISOTUMAB VEDOTIN) | Pfizer | $704K | 86% | PEAK | Stable | |
| 2 | ZYCLARA (IMIQUIMOD) | Bausch + Lomb | $115K | 14% | PEAK | Stable | 3.9yr |
Drug Class Breakdown
market-defining
patent cliff pending 2030
Career Outlook
StableCervical cancer is a therapeutically validated but commercially modest market with intense concentration in a single Pfizer asset. The field offers stable, specialized roles but limited near-term growth; career advancement depends on pipeline success or cross-indication opportunities. This is a specialist track best suited for candidates with strong oncology foundations seeking deep disease expertise rather than rapid advancement.
Breaking In
Enter through a large oncology player (Pfizer, Novartis, AstraZeneca) with a commercial or R&D role in oncology broadly, then specialize in cervical cancer to build deep expertise.
For Experienced Professionals
Experienced oncology professionals should evaluate whether pipeline catalysts justify staying in this niche or lateral-moving to higher-growth indications; consider roles in medical affairs or market access if targeting long-term stability.
In-Demand Skills
Best For
Hiring Landscape
5,302 jobs are available across oncology-focused companies, but only a fraction target cervical cancer specialists. Pfizer and Novartis are primary employers with 542 and 622 jobs respectively (company-wide oncology roles). Commercial departments dominate hiring (1,077 jobs) at an average salary of $257K, reflecting need for field-level expertise.
Top Hiring Companies
By Department
Cervical cancer specialists will find jobs primarily in commercial and R&D roles at larger oncology-focused organizations, with commercial positions commanding premium salaries.
On Market (1)
Approved therapies currently available
Competitive Landscape
58 companies ranked by most advanced pipeline stage
+28 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 69,817 patients across 50 trials
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury
CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)
Trial to Optimally Show the Pharmacological Action of Z-100
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer
Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Online Adaptive Radiotherapy for Cervical Cancer
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
Dostarlimab and Cobolimab in Advanced Cervical Cancer
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies
A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Rucaparib Maintenance Therapy in Advanced Cervical Cancer
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
Related Jobs in Oncology
Global Medical Affairs Lead, Cervical Cancer Screening
Area Sales Manager
Application Specialist- Diagnostics
Area Sales Manager
Pricing Analyst
Senior Business-oriented Data Engineer
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.